128 related articles for article (PubMed ID: 29255349)
1. Preparation and evaluation of RGD and TAT co-modified docetaxel-loaded liposome.
Zhu R; Tian Y
Drug Des Devel Ther; 2017; 11():3481-3489. PubMed ID: 29255349
[TBL] [Abstract][Full Text] [Related]
2. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
3. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
4. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.
Jiang K; Shen M; Xu W
Int J Nanomedicine; 2018; 13():2561-2569. PubMed ID: 29731631
[TBL] [Abstract][Full Text] [Related]
5. [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
Gao B; Mu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 39(8):769-74. PubMed ID: 25202944
[TBL] [Abstract][Full Text] [Related]
6. RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro.
Zuo T; Guan Y; Chang M; Zhang F; Lu S; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2016 Nov; 147():90-99. PubMed ID: 27497073
[TBL] [Abstract][Full Text] [Related]
7. TAT modified and lipid - PEI hybrid nanoparticles for co-delivery of docetaxel and pDNA.
Dong S; Zhou X; Yang J
Biomed Pharmacother; 2016 Dec; 84():954-961. PubMed ID: 27764758
[TBL] [Abstract][Full Text] [Related]
8. Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel.
Li B; Zhang XX; Huang HY; Chen LQ; Cui JH; Liu Y; Jin H; Lee BJ; Cao QR
Int J Pharm; 2018 May; 543(1-2):8-20. PubMed ID: 29535039
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
10. Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting.
Choi JS; Park JS
Drug Des Devel Ther; 2017; 11():17-26. PubMed ID: 28031702
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.
Tong SW; Xiang B; Dong DW; Qi XR
Int J Pharm; 2012 Sep; 434(1-2):413-9. PubMed ID: 22698861
[TBL] [Abstract][Full Text] [Related]
13. Combined integrin α
Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
[TBL] [Abstract][Full Text] [Related]
14. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
15. Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting.
Ma J; Zhuang H; Zhuang Z; Lu Y; Xia R; Gan L; Wu Y
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1864-1871. PubMed ID: 29082764
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
Jiang S; Gong X; Zhao X; Zu Y
Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
[TBL] [Abstract][Full Text] [Related]
17. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel.
Zhang H; Gong W; Wang ZY; Yuan SJ; Xie XY; Yang YF; Yang Y; Wang SS; Yang DX; Xuan ZX; Mei XG
J Pharm Sci; 2014 Jul; 103(7):2177-2183. PubMed ID: 24846075
[TBL] [Abstract][Full Text] [Related]
19. Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation.
Zhao Z; Zhao Y; Xie C; Chen C; Lin D; Wang S; Lin D; Cui X; Guo Z; Zhou J
Chem Phys Lipids; 2019 Sep; 223():104785. PubMed ID: 31194968
[TBL] [Abstract][Full Text] [Related]
20. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Gu Z; Chang M; Fan Y; Shi Y; Lin G
Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
